Market revenue in 2022 | USD 3,451.8 million |
Market revenue in 2030 | USD 23,532.7 million |
Growth rate | 27.1% (CAGR from 2022 to 2030) |
Largest segment | Cell therapy |
Fastest growing segment | Gene Therapy |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy |
Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 57.55% in 2022. Horizon Databook has segmented the North America cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
North America dominated cell and gene therapy manufacturing market in 2019 with the largest revenue share. This can be attributed to growing engagement of companies in research and product development in gene & cell therapy coupled with a substantial number of contract development organizations in the region.
In addition, homegrown companies are expanding their manufacturing facilities in the region. For instance, a US-based pharmaceutical company, Pfizer, expanded its gene therapy manufacturing facility in North Carolina.
The construction of this facility commenced in 2018, and it is operational since January 2020. Such initiatives are anticipated to fuel market growth in the region. On the other hand, currently, more than 400 companies in the region are actively engaged in development of cell & gene therapy products for various diseases.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America cell and gene therapy manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into North America cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account